SCHEMBL29935534

SCHEMBL29935534

FC(F)(F)c1ccc(O[C@H]2CCN(c3ccc(-c4ccccc4)cc3)C2)nc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 1/20 0.59
LIPE Q05469 6/20 0.50
MET P08581 1/20 0.44
HSD11B1 P28845 3/20 0.44
CYP3A4 P08684 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
NOTUM Q6P988 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
OXTR P30559 1/20 0.42
AVPR1A P37288 1/20 0.42
HCRTR1 O43613 1/20 0.42
HCRTR2 O43614 1/20 0.42
CCR6 P51684 1/20 0.41
ACACB O00763 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL23703282 0.99 LIPG (0.58) LIPGLIPEMETHSD11B1CYP3A4
SCHEMBL29935625 0.91 LIPG (0.57) LIPGLIPEHSD11B1HRH3ACACB
SCHEMBL29240875 0.90 LIPG (0.56) LIPGLIPEMETHSD11B1CYP3A4
SCHEMBL29240874 0.90 LIPG (0.56) LIPGLIPEMETHSD11B1CYP3A4
SCHEMBL29240903 0.89 LIPG (0.57) LIPGLIPEMETHSD11B1HRH3
SCHEMBL29240907 0.89 LIPG (0.57) LIPGLIPEMETHSD11B1HRH3
SCHEMBL29935520 0.88 LIPG (0.52) LIPGLIPEMETHSD11B1GAA
SCHEMBL29994462 0.88 LIPG (0.52) LIPGLIPEMETHSD11B1HRH3
SCHEMBL29935476 0.86 LIPG (0.55) LIPGLIPEMETHSD11B1GAA
SCHEMBL7956252 0.85 LIPG (0.60) LIPGLIPEHSD11B1CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220332697-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS KAMARI PHARMA LTD. (IL) 2022-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332697-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS RDX, HAX1, F12 LIPG 1423/4885LIPE 3173/4885MET 4609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.